Physician

Annette C Fontaine, MD

According to 2025 Medicare claims, Annette Fontaine, MD (NPI: 1346234788) practices hematology/oncology in the Albuquerque, NM market, with the plurality of this provider's patient population coming from Bernalillo, NM. This provider's primary affiliated billing organization is NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (NPI: 1164475232; TIN: 850367056) and primary practice location at 87109-4495. Fontaine is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Fontaine's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 676 traditional Medicare patients, billed 96,870 HCPCS/CPT codes, and received $1,448,352 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,628 prescription claims across 261 beneficiaries totaling $4,192,067 in drug costs, led by Ibrance (Palbociclib). DME data shows 43 claims. Open Payments data shows 51 records totaling $57,548. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,606,628 to $4,192,067. In contrast, DME billing represents a smaller volume and declined steadily, from $5,306 to $1,770.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	690	119,517	$1,426,237
2016	643	68,323	$1,040,306
2017	804	84,742	$1,540,066
2018	809	102,881	$2,081,170
2019	725	110,212	$2,011,126
2020	610	94,225	$2,047,925
2021	720	121,061	$1,871,539
2022	880	116,681	$2,297,368
2023	786	132,564	$2,233,671
2024	676	96,870	$1,448,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	278	1,805	$1,606,628
2016	265	1,444	$1,528,609
2017	287	1,508	$1,576,472
2018	294	1,798	$2,706,998
2019	282	1,978	$4,383,888
2020	271	1,934	$4,901,506
2021	266	1,840	$5,110,560
2022	294	2,057	$6,081,429
2023	276	1,734	$5,049,716
2024	261	1,628	$4,192,067

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	112	$37,659
2016	11	96	$24,575
2017	11	97	$15,480
2018	N/R	98	$8,173
2019	N/R	71	$5,787
2020	N/R	146	$8,764
2021	N/R	141	$8,043
2022	N/R	80	$2,478
2023	N/R	12	$711
2024	N/R	43	$940

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	200	461	$128
96413	Administration of chemotherapy into vein, 1 hour or less	88	201	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	199	244	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	106	118	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	340	508	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	51	1,428	$801,636
Jakafi	Ruxolitinib Phosphate	33	990	$585,343
Lenalidomide	Lenalidomide	25	700	$415,698
Kisqali	Ribociclib Succinate	23	553	$284,937
Revlimid	Lenalidomide	13	364	$276,127

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	16	$507
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	50	$24,338	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$33,210	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Annette C. Fontaine, MD?

Tedicare shows public-source Medicare data for Annette C. Fontaine, MD (NPI 1346234788), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Annette C. Fontaine, MD have ACO affiliation data?

Annette C. Fontaine, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Annette C. Fontaine, MD?

Annette C. Fontaine, MD is linked to NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (billing NPI 1164475232) in the available physician profile data.

Does Annette C. Fontaine, MD have Open Payments data?

Annette C. Fontaine, MD has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.